The Hetero Ring Is Six-membered And Includes At Least Two Nitrogens And No Other Hetero Atoms Patents (Class 514/157)
-
Patent number: 12097261Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.Type: GrantFiled: May 6, 2022Date of Patent: September 24, 2024Assignee: Kymera Therapeutics, Inc.Inventors: Xiaozhang Zheng, Yi Zhang, Robert Aversa, Xiao Zhu, Philip Collier
-
Patent number: 12031011Abstract: Disclosed are a poly dopamine film and a preparation method and application thereof. The polydopamine film is loaded with silver sulfadiazine, and the preparation method achieves in-situ synthesis of si sulfadiazine on a conventional polydopamine film by microwave irradiation. In the method, the sulfadiazine is not dissolved in conventional aqueous ammonia, which has the following advantages: firstly, preventing the polydopamine film from being corroded by the aqueous ammonia; secondly, protecting mucosa such as eyes and nasal cavities of workers from stimulation and corrosion of the aqueous ammonia; and thirdly, avoiding the environmental problem caused by pungent odor and fumes emitted from high-concentration aqueous ammonia. In the method, without using the catalyst trifluoromethanesulfonic acid or trifluoromethanesulfonic salt, not only is the loading of silver sulfadiazine increased, but also the safely performance can be further improved.Type: GrantFiled: July 15, 2020Date of Patent: July 9, 2024Assignee: B. J. ZH. F. PANTHER MEDICAL EQUIPMENT CO., LTD.Inventors: Qing Liu, Cong Pu
-
Patent number: 11945769Abstract: The present invention relates to an N,N?-diurea derivative represented by the following general formula (1) and a method for producing the same. In addition, the present invention relates to a thermosensitive recording material in which a thermosensitive recording layer including a basic dye which is colorless or lightly colored at room temperature and a developer capable of developing color upon contact with the basic dye by heating is provided on a base sheet, wherein the developer is the N,N?-diurea derivative represented by the following general formula (1): (wherein R2 is an alkyl group, an aralkyl group, or an aryl group; and A1 is a hydrogen atom or an alkyl group).Type: GrantFiled: August 10, 2018Date of Patent: April 2, 2024Assignee: SANKO CO., LTD.Inventors: Ryoichi Kinishi, Yoshimi Ishibashi
-
Patent number: 11865123Abstract: This invention is based on the discovery that many eye conditions associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The data show that in age-matched patients, the severity of age-related conditions correlates with the abundance of senescent cells, and that clearing senescent cells can help abrogate the condition. Small molecule drugs that remove senescent cells from affected tissue in the eye are provided that have special efficacy in treating ophthalmic conditions. They not only inhibit progression of the disease, they can also reverse some of the pathophysiology—such as neovascularization and vaso-obliteration—that lead to vision loss. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable ophthalmic conditions.Type: GrantFiled: August 25, 2021Date of Patent: January 9, 2024Assignee: Unity Biotechnology, Inc.Inventors: Pam Tsuruda, Jill Hopkins, Harry Sweigard, Yan Poon, Jamie Dananberg, Daniel Marquess, Nathaniel David
-
Patent number: 11236046Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: October 18, 2019Date of Patent: February 1, 2022Assignee: Genentech, Inc.Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
-
Patent number: 11208381Abstract: The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.Type: GrantFiled: June 1, 2020Date of Patent: December 28, 2021Assignee: RESPIVERT LIMITEDInventors: Iain Walters, Louise Birch, Stephen Paul Collingwood, Christopher Scott Stevenson
-
Patent number: 10669235Abstract: The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of fibrotic diseases or interstitial lung diseases, in particular idiopathic pulmonary fibrosis.Type: GrantFiled: March 8, 2017Date of Patent: June 2, 2020Assignee: RESPIVERT LIMITEDInventors: Iain Walters, Louise Birch, Stephen Paul Collingwood, Christopher Scott Stevenson
-
Patent number: 10479793Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.Type: GrantFiled: November 17, 2016Date of Patent: November 19, 2019Assignee: Bristol-Myers Squibb CompanyInventors: David S. Weinstein, Ryan M. Moslin, Yanlei Zhang, Daniel S. Gardner, Joseph B. Santella, Charles M. Langevine, Sylwia Stachura
-
Patent number: 10383876Abstract: The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and—to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agentType: GrantFiled: March 29, 2012Date of Patent: August 20, 2019Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
-
Patent number: 10335408Abstract: Compositions and methods of using nintedanib for improving the success rate of glaucoma filtration surgery are disclosed herein. Nintedanib can be used alone or in combination with an anti-metabolite drug in a topical or implant eye formulation.Type: GrantFiled: September 14, 2018Date of Patent: July 2, 2019Assignee: Cloudbreak Therapeutics, LLCInventors: Jinsong Ni, Rong Yang
-
Patent number: 10221174Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.Type: GrantFiled: August 1, 2018Date of Patent: March 5, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Shaomeng Wang, Jianyong Chen
-
Patent number: 9993485Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.Type: GrantFiled: October 29, 2014Date of Patent: June 12, 2018Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Martin A. Folger, Stefan Henke, Bernhard Hassel, Bernd Zierenberg
-
Patent number: 9737559Abstract: The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular, the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (DP) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of Type-2 Diabetes Meliitus (T2DM). Said compositions are also used for preventing the development of, or ameliorating, side-effects or conditions in a subject treated with sulfonylurea and/or a sulfonamide compounds (and/or derivatives and/or metabolites thereof, or combinations thereof), said side-effects including hypoglycemia, gastrointestinal disturbances, fatigue, weight gain, and satiety.Type: GrantFiled: November 23, 2012Date of Patent: August 22, 2017Assignee: Ozstar Therapeutics Pty LtdInventor: Nick Naser Gorgani
-
Patent number: 9676708Abstract: Protected HNO donors designed to undergo non-enzymatic release at neutral pH via an intramolecular cyclization-elimination are disclosed. The rate of cyclization, and therefore HNO release, can be controlled by substituents and chain length. Thus, biologically useful HNO donors having tunable HNO release rates are provided.Type: GrantFiled: October 30, 2013Date of Patent: June 13, 2017Assignee: The Johns Hopkins UniversityInventors: John P. Toscano, Art D. Sutton
-
Patent number: 9439423Abstract: An antiparasitic agent for fish includes an inhibitor of folate synthesis and/or an inhibitor of folate activation as the active substance(s). A combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is disclosed. Sulfonamide is disclosed as suitable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist are disclosed as suitable inhibitors of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is effective against fish parasites belonging to the ciliate group.Type: GrantFiled: October 29, 2008Date of Patent: September 13, 2016Assignee: NIPPON SUISAN KAISHA, LTD.Inventors: Fumi Kawano, Noritaka Hirazawa
-
Patent number: 9315459Abstract: Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.Type: GrantFiled: November 14, 2014Date of Patent: April 19, 2016Assignee: H. Lundbeck A/SInventors: Benny Bang-Andersen, Andre Faldt, Tine Bryan Stensbol, Silke Miller, Heidi Lopez De Diego
-
Patent number: 9265777Abstract: A method of controlling proliferation of fish parasites comprising the administration of 1 to 50 mg/kg fish body weight/day of an inhibitor of folate synthesis and/or an inhibitor of folate activation to fish continuously for 1 to 2 weeks. Using a combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation. The antiparasitic agent is able to exterminate fish parasites via oral administration. It is particularly effective against parasites belonging to the ciliate group among fish parasites.Type: GrantFiled: April 26, 2010Date of Patent: February 23, 2016Assignee: NIPPON SUISAN KAISHA, LTD.Inventors: Fumi Kawano, Noritaka Hirazawa
-
Patent number: 9125833Abstract: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.Type: GrantFiled: April 26, 2008Date of Patent: September 8, 2015Assignee: Relmada Therapeutics, Inc.Inventor: Najib Babul
-
Patent number: 9060952Abstract: The present invention is a preservative formulation which includes a combination of at least two (2) compounds having bactericidal and/or fungicidal properties wherein the at least two (2) compounds is selected from the group consisting of methylisothiazolinone/piroctone olamine; caprylyl glycol/dehydroacetic acid; undecanol/dehydroacetic acid and lauryl alcohol/sorbic acid. The invention also includes preparations including such combination as well as a method of using the combination to reduce bacterial and fungal load of preparations.Type: GrantFiled: May 20, 2009Date of Patent: June 23, 2015Assignee: LONZA LTD.Inventors: Rosita Nunez, Larry Kent Hall, Crystal Maira, Joseph Kimler, Craig Carter
-
Publication number: 20150111857Abstract: Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Douglas Wilson, Yulian Zhang
-
Publication number: 20150094283Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.Type: ApplicationFiled: December 10, 2014Publication date: April 2, 2015Inventor: Rakesh KUMAR
-
Patent number: 8946197Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.Type: GrantFiled: November 12, 2010Date of Patent: February 3, 2015Assignee: CHDI Foundation, Inc.Inventors: Celia Dominguez, John Wityak, Michael Prime, Stephen Martin Courtney, Christopher Yarnold, Frederick Brookfield, Richard Marston, Douglas Macdonald
-
Publication number: 20150031652Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.Type: ApplicationFiled: August 1, 2014Publication date: January 29, 2015Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
-
Publication number: 20150005265Abstract: The present invention provides methods and compositions for treating cancers using a combination of a CYP 1 7 inhibitor and an additional therapeutic agent which modulates the PBK/Akt/mTOR pathway. In one aspect, the invention provides methods for the treatment of a disorder in a human subject. In some embodiments, the disorder is a neoplastic disorder. In some embodiments, the neoplastic disorder is a cancer. In some embodiments, the method comprises administering to said subject a 17a-hydroxylase/C17,20-lyase inhibitor (CYP17 inhibitor) and an additional agent, wherein the additional agent is a PBK inhibitor and/or mTOR inhibitor.Type: ApplicationFiled: December 21, 2012Publication date: January 1, 2015Inventor: Susan Stewart
-
Patent number: 8921521Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: December 17, 2012Date of Patent: December 30, 2014Assignee: Ocera Therapeutics, Inc.Inventors: Eric Marsault, Carl St-Louis
-
Patent number: 8883766Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels.Type: GrantFiled: April 27, 2012Date of Patent: November 11, 2014Assignee: Vertex Pharmaceuticals IncorporatedInventors: Esther Martinborough, Tim Neubert, Tara Whitney, Danielle Lehsten, Tara Hampton, Nicole Zimmermann, Andreas P. Termin
-
Patent number: 8871248Abstract: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.Type: GrantFiled: November 26, 2012Date of Patent: October 28, 2014Assignee: PluroGen Therapeutics, Inc.Inventors: George Rodeheaver, Adam Katz
-
Publication number: 20140243295Abstract: The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity anType: ApplicationFiled: March 29, 2012Publication date: August 28, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Ningshu Liu, Claudia Schneider
-
Patent number: 8796001Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.Type: GrantFiled: June 19, 2012Date of Patent: August 5, 2014Assignee: Viamet Pharmaceuticals, Inc.Inventors: William J. Hoekstra, Christopher M. Yates, Robert J. Schotzinger, Michael R. Loso, Zachary A. Buchan, Michael T. Sullenberger
-
Patent number: 8691573Abstract: The present invention relates compounds for stabilizing cells and methods of their use.Type: GrantFiled: December 3, 2009Date of Patent: April 8, 2014Assignee: The Scripps Research InstituteInventors: Yue Xu, Sheng Ding
-
Publication number: 20140018326Abstract: Compounds of Formula I are disclosed: wherein L, A, R1, R2, R3A, R3B, R4A, R4B, R5, R6 and R7 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: October 27, 2011Publication date: January 16, 2014Inventors: Oscar M. Moradei, Sheldon Crane, Daniel J. Mckay, Marie-Eve Lebrun, Vouy Linh Truong
-
Patent number: 8628751Abstract: The invention provides compounds, including compositions, preparations and formulations, and methods of using and making such compounds. Compounds of the present invention include pyrazine derivatives having a pyrazine core and a plurality of substituents. In some embodiments, pyrazine derivatives of the invention are pyrazine core compounds having one or more electron donating groups and one or more electron withdrawing groups optionally functionalized to provide useful optical, biological, pharmacokinetic and/or physical properties.Type: GrantFiled: April 15, 2010Date of Patent: January 14, 2014Assignee: Medi Beacon Development, LLCInventors: William L. Neumann, John N. Freskos
-
Publication number: 20140011770Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.Type: ApplicationFiled: September 10, 2013Publication date: January 9, 2014Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
-
Publication number: 20130345180Abstract: There are provided compounds of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as indicated in claim 1, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.Type: ApplicationFiled: March 15, 2013Publication date: December 26, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Publication number: 20130310344Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.Type: ApplicationFiled: August 5, 2011Publication date: November 21, 2013Applicant: ASTRAZENECA ABInventors: Robert Bruce Diebold, Thomas Gero, Paul Grover, Shan Huang, Stephanos Ioannidis, Claude Afona Ogoe, Jamal Carlos Saeh, Jeffrey Gilbert Varnes
-
Publication number: 20130310348Abstract: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQR or CQS Plasmodium sp. (such as P. falciparum).Type: ApplicationFiled: July 25, 2013Publication date: November 21, 2013Applicants: State UniversityInventors: David H. Peyton, Steven Burgess
-
Publication number: 20130303491Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.Type: ApplicationFiled: July 22, 2013Publication date: November 14, 2013Applicant: Siga Technologies Inc.Inventors: Chelsea M. Byrd, Robert Jordan, Dongcheng Dai, Tove Bolken, Dennis E. Hruby
-
Publication number: 20130281403Abstract: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.Type: ApplicationFiled: June 7, 2013Publication date: October 24, 2013Inventors: Arnab K. Chatterjee, Advait S. Nagle, Tao Wu, David C. Tully, Kelli L. Kuhen
-
Publication number: 20130190258Abstract: Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R1, R2, R2?, R3, R4, R5, R6, R7, R8, R9 are as described herein.Type: ApplicationFiled: January 24, 2013Publication date: July 25, 2013Inventors: John CASHMAN, Mark MERCOLA, Dennis SCHADE, Masanao TSUDA
-
Patent number: 8481001Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.Type: GrantFiled: April 8, 2008Date of Patent: July 9, 2013Assignee: Exelixis, Inc.Inventors: Peter Lamb, David Matthews
-
Publication number: 20130150334Abstract: Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.Type: ApplicationFiled: December 6, 2012Publication date: June 13, 2013Applicant: Rigel Pharmaceuticals, Inc.Inventor: Rigel Pharmaceuticals, Inc.
-
Patent number: 8454984Abstract: Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional acrylic monomer, about 5 weight % to about 40 weight % of an adhesion-promoting acrylic or vinyl monomer, and about 0.1 weight % to about 15 weight % of a metal salt; and exposing the mixture to a radiation source to cure at least a portion of the mixture, thereby forming an antimicrobial resin.Type: GrantFiled: September 11, 2012Date of Patent: June 4, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Vadim V. Krongauz, Dustin C. Cawthon, Michael Tung-Kiung Ling
-
Publication number: 20130116216Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.Type: ApplicationFiled: November 12, 2010Publication date: May 9, 2013Inventors: Celia Dominguez, John Wityak, Michael Prime, Stephen Martin Courtney, Christopher Yarnold, Frederick Brookfield, Richard Marston, Douglas Macdonald
-
Publication number: 20130101661Abstract: Compositions containing a surface active agent and a sub-lethal amount of an antimicrobial agent and methods for using such compositions are provided herein.Type: ApplicationFiled: November 26, 2012Publication date: April 25, 2013Applicant: PLUROGEN THERAPEUTICS, INC.Inventor: PLUROGEN THERAPEUTICS, INC.
-
Publication number: 20130053333Abstract: This invention relates to novel aminoquinoline derivatives of Formula (I) or Ia, or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an aminoquinoline derivative, such as a derivative of primaquine.Type: ApplicationFiled: January 19, 2011Publication date: February 28, 2013Inventor: Roger D. Tung
-
Publication number: 20130035310Abstract: The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.Type: ApplicationFiled: October 2, 2012Publication date: February 7, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Esther Ann Martinborough, Lev Tyler Dewey Fanning, Urvi Jagdishbhai Sheth, Dean Mitchell Wilson, Andreas P. Termin, Timothy Donald Neubert, Nicole Hilgraf, Tara Leanne Hampton, Tara Whitney, Aarti Sameer Kawatkar, Danielle Lehsten, Dean Stamos, Jinglan Zhou, Vijayalaksmi Arumugam, Corey Anderson
-
Publication number: 20130029944Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.Type: ApplicationFiled: June 20, 2012Publication date: January 31, 2013Applicant: Portola Pharmaceuticals, Inc.Inventors: Yonghong Song, Qing Xu, Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Anjali Pandey
-
Publication number: 20130023499Abstract: Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B-cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample.Type: ApplicationFiled: January 4, 2012Publication date: January 24, 2013Applicant: Gilead Connecticut, Inc.Inventors: Scott A. MITCHELL, Kevin S. CURRIE, Peter A. BLOMGREN, David M. ARMISTEAD, Joseph RAKER
-
Publication number: 20130023497Abstract: The present invention comprises inter alia triazine compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 7, 2010Publication date: January 24, 2013Inventors: Chunlin Tao, Qinwei Wang, Tulay Polat, Laxman Nallan, Neil Desai
-
Publication number: 20130004557Abstract: Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional acrylic monomer, about 5 weight % to about 40 weight % of an adhesion-promoting acrylic or vinyl monomer, and about 0.1 weight % to about 15 weight % of a metal salt; and exposing the mixture to a radiation source to cure at least a portion of the mixture, thereby forming an antimicrobial resin.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicants: BAXTER INTERNATIONAL INC.Inventors: Vadim V. Krongauz, Dustin C. Cawthon, Michael Tung-Kiung Ling